Years after a major trial setback, Novartis switches gears with SMA drug. This time...

cafead

Administrator
Staff member
  • cafead   Oct 22, 2020 at 12:02: AM
via Four years after a Phase I/II setback in spinal muscular atrophy (SMA), Novartis is hoping its drug branaplam will find more success in a new neurological indication: Huntington’s disease.

article source
 

<